|
Childhood Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data indicated that DPYSL3, not DPYSL1 or DPYSL2, is negatively regulated by MYCN and may be used as a potential biomarker for NB.
|
24011394 |
2013 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Characterization of the roles of dihydropyrimidinase-like 3 in relation to cancer cell adhesion and migration in vitro, and metastasis in vivo was performed using a series of functional analyses, including those employing multiple reaction monitoring proteomic analysis.
|
24339867 |
2013 |
|
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, dihydropyrimidinase-like 3 was found to interact with Ezrin, which has important roles in cell adhesion, motility, and invasion, while that interaction promoted stabilization of an adhesion complex consisting of Ezrin, c-Src, focal adhesion kinase, and Talin1.
|
24339867 |
2013 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Characterization of the roles of dihydropyrimidinase-like 3 in relation to cancer cell adhesion and migration in vitro, and metastasis in vivo was performed using a series of functional analyses, including those employing multiple reaction monitoring proteomic analysis.
|
24339867 |
2013 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Characterization of the roles of dihydropyrimidinase-like 3 in relation to cancer cell adhesion and migration in vitro, and metastasis in vivo was performed using a series of functional analyses, including those employing multiple reaction monitoring proteomic analysis.
|
24339867 |
2013 |
|
Pancreatic Ductal Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Quantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinoma-associated molecule that regulates cell adhesion and migration by stabilization of focal adhesion complex.
|
24339867 |
2013 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
GC tissues from tumors with distant metastases (stage IV cancer) showed elevated expression levels of DPYSL3 mRNA.
|
25096402 |
2014 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
GC tissues from tumors with distant metastases (stage IV cancer) showed elevated expression levels of DPYSL3 mRNA.
|
25096402 |
2014 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
GC tissues from tumors with distant metastases (stage IV cancer) showed elevated expression levels of DPYSL3 mRNA.
|
25096402 |
2014 |
|
Secondary Neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
GC tissues from tumors with distant metastases (stage IV cancer) showed elevated expression levels of DPYSL3 mRNA.
|
25096402 |
2014 |
|
Malignant neoplasm of stomach
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
High DPYSL3 mRNA expression in GCs was significantly associated with more malignant phenotypes and was an independent prognostic factor.
|
25096402 |
2014 |
|
Stomach Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
High DPYSL3 mRNA expression in GCs was significantly associated with more malignant phenotypes and was an independent prognostic factor.
|
25096402 |
2014 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Dihydropyrimidinase-like 3 (DPYSL3) suppresses cell proliferation and tumorigenicity of certain malignancies; however, its role in HCC is unknown.
|
25173447 |
2015 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Our results indicate that DPYSL3 is a putative HCC tumor suppressor, and promoter hypermethylation potently regulates DPYSL3 transcription.
|
25173447 |
2015 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
DPYSL3 mRNA levels were down-regulated in most HCC cell lines with DPYSL3 promoter hypermethylation, and expression was restored after demethylation.
|
25173447 |
2015 |
|
Malignant neoplasm of prostate
|
0.080 |
Biomarker
|
disease |
BEFREE |
Taken together, our research indicated CRMP4 inhibits prostate cancer cells growth in the nude mouse bone microenvironment and this effect may relate with regulation of NRP1 and Noggin expression.
|
25338524 |
2015 |
|
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Our previous study showed collapsin response mediator protein 4 (CRMP4) gene inhibited prostate cancer migration and invasion.
|
25338524 |
2015 |
|
Prostate carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Taken together, our research indicated CRMP4 inhibits prostate cancer cells growth in the nude mouse bone microenvironment and this effect may relate with regulation of NRP1 and Noggin expression.
|
25338524 |
2015 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Small animal PET/CT scanning results showed no difference of bone metastatic capacity in orthotopic and intracardiac injection models between CRMP4 overexpression and control group, while CRMP4 overexpression inhibited tumor growth in the intratibial injection model.
|
25338524 |
2015 |
|
Lentivirus Infections
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The stable prostate cancer cells overexpressing the CRMP4 gene were constructed using lentivirus infection.
|
25338524 |
2015 |
|
Secondary malignant neoplasm of bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated whether overexpression of CRMP4 gene in prostate cancer cells inhibit tumor bone metastasis.
|
25338524 |
2015 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This proof-of-concept study with dTALEs for locus-specific epigenomic manipulation validates the selected CpG methylation of CRMP4 gene as an independent biomarker for diagnosis and prognosis of prostate cancer metastasis and opens up a novel avenue for mechanistic research on cancer biology.
|
25888628 |
2015 |
|
Malignant neoplasm of prostate
|
0.080 |
Biomarker
|
disease |
BEFREE |
This proof-of-concept study with dTALEs for locus-specific epigenomic manipulation validates the selected CpG methylation of CRMP4 gene as an independent biomarker for diagnosis and prognosis of prostate cancer metastasis and opens up a novel avenue for mechanistic research on cancer biology.
|
25888628 |
2015 |
|
Prostate carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
This proof-of-concept study with dTALEs for locus-specific epigenomic manipulation validates the selected CpG methylation of CRMP4 gene as an independent biomarker for diagnosis and prognosis of prostate cancer metastasis and opens up a novel avenue for mechanistic research on cancer biology.
|
25888628 |
2015 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
This proof-of-concept study with dTALEs for locus-specific epigenomic manipulation validates the selected CpG methylation of CRMP4 gene as an independent biomarker for diagnosis and prognosis of prostate cancer metastasis and opens up a novel avenue for mechanistic research on cancer biology.
|
25888628 |
2015 |